Floatz Rating
BB64/100
Confidence
Indicative
Sponsor
Zhejiang University
Modality
monoclonal_antibody
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
61High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07257653CT.gov The Safety and Efficacy of Cetuximab Beta Plus Fruquintinib With or Without Immune Checkpoint Inhibitorrs in First-line Treatment of RAS/BRAF Wild Type Unresectable Metastatic Colorectal Cancer | — | Recruiting | — | — | — |
NCT06750094CT.gov A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy | — | Recruiting | — | — | — |
NCT06704724CT.gov A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene. | — | Terminated | — | — | — |
NCT06662786CT.gov A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer | — | Recruiting | — | — | — |
NCT06447662CT.gov A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation. | — | Recruiting | — | — | — |
NCT06640166CT.gov Encorafenib + Cetuximab Beyond Progression in Combination With FOLFIRI in Patients With BRAF V600E Mutated Metastatic Colorectal Cancer Progressing on Encorafenib + Cetuximab. | — | Recruiting | — | — | — |
NCT06226857CT.gov Other Oncogene Mutations for Anti-EGFR Efficacy in Patients With Left-sided RAS-wild Type Metastatic Colorectal Cancer | — | Recruiting | — | — | — |
NCT05253651CT.gov A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer | — | Recruiting | — | — | — |
NCT05358249CT.gov Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation | — | Active Not Recruiting | — | — | — |
NCT05239741CT.gov Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Colorectal Cancer (MK-3475-C66) | — | Active Not Recruiting | — | — | — |
Show 17 more trialsShow fewer
NCT04956640CT.gov Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C) | — | Active Not Recruiting | — | — | — |
NCT05143099CT.gov Phase II Study of Tislelizumab Combined With Cetuximab and Irinotecan in the Treatment of Recurrent, Refractory mCRC | — | Unknown | — | — | — |
NCT04515394CT.gov Study of Tepotinib Combined With Cetuximab in Participants With Left-Sided RAS/BRAF Wild Type Metastatic Colorectal Cancer (PERSPECTIVE) | — | Terminated | — | — | — |
NCT02124148CT.gov A Study of Prexasertib (LY2606368) With Chemotherapy or Targeted Agents in Participants With Advanced Cancer | — | Completed | — | — | — |
NCT01450319CT.gov Cetuximab in Refractory Colorectal Cancer With K-RAS Mutated and Favorable FcγRIIa (CD32) Genotype | — | Completed | — | — | — |
NCT01152437CT.gov A Study of BIBW 2992 (Afatinib) in Patients With Metastatic Colorectal Cancer | — | Completed | — | — | — |
NCT01134666CT.gov An Observational Study to Evaluate the Safety and Efficacy of FOLFIRI / FOLFOX Plus Cetuximab as First-line Therapy in Patients With KRAS Wild-type Metastatic Colorectal Cancer | — | Terminated | — | — | — |
NCT01082315CT.gov A Korean Post-marketing Surveillance Study on Erbitux® in Patients With Metastatic Colorectal Cancer Refractory to Irinotecan-containing Treatment | — | Completed | — | — | — |
NCT01074333CT.gov An Observational Study of Erbitux® in Patients With Metastatic Colorectal Cancer (mCRC) Refractory to Irinotecan-containing Treatment | — | Terminated | — | — | — |
NCT00540943CT.gov Study of Pazopanib, Irinotecan and Cetuximab in Combination to Treat 2nd Line Metastatic Colorectal Cancer | — | Completed | — | — | — |
NCT00478634CT.gov A Phase 1 Study Investigating the Combination of RAD001, Cetuximab and Irinotecan as Second-line Therapy After FOLFOX (or XELOX) Plus Bevacizumab in Patients With Metastatic Colorectal Cancer | — | Completed | — | — | — |
NCT00437268CT.gov A Study of Irinotecan Plus Cetuximab With or Without Enzastaurin in Participants With Colorectal Cancer | — | Completed | — | — | — |
NCT01564810CT.gov Cetuximab in Combination With Chemotherapy for the Treatment of Metastatic Colorectal Cancer | — | Unknown | — | — | — |
NCT00321100CT.gov Combination of Cetuximab, Capecitabine, and Oxaliplatin With or Without Bevacizumab | — | Terminated | — | — | — |
NCT00083720CT.gov Erbitux (Cetuximab) Given Alone to Patients With EGFR-Negative Metastatic Colon or Rectal Cancer That is Refractory to Chemotherapy | — | Completed | — | — | — |
NCT00055419CT.gov A Study of Cetuximab in Patients Who Have Stage IV Colorectal Cancer | — | Completed | — | — | — |
NCT00044863CT.gov Study of Erbitux (Cetuximab) in Patients With Metastatic Colorectal Carcinoma | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Colorectal Neoplasm
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Cetuximab (this asset) | Zhejiang University | Approved | BB · 64 |
| Fluorouracilum | Rutgers, The State University of New Jersey | P4 | BBB |
| Oxaliplatin | Peking University Cancer Hospital & Institute | P4 | BBB |
| Ferric Carboxymaltose [Ferinject] | Nottingham University Hospitals NHS Trust | P4 | BBB |
| Irinotecan | Shanghai Zhongshan Hospital | P4 | BBB |
| Capecitabine | Rutgers, The State University of New Jersey | P4 | BB |
| Regorafenib | Sergey Orlov, MD | P4 | BB |
| Nivolumab | Bristol-Myers Squibb | P3 | BB |
| Iron(Ii) Sulphate (1:1), Heptahydrate | Nottingham University Hospitals NHS Trust | P4 | BB |
+41 more in the Colorectal Neoplasm cohort
Other indications for Cetuximab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Colon Adenocarcinoma | — | P3 | BB · 70 |
| Rectal Carcinoma | — | P2 | BB · 69 |
| Non-Small Cell Lung Carcinoma | — | P3 | BB · 69 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Cetuximab in Colorectal Neoplasm. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 11, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/cetuximab-colorectal-neoplasm
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →